Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
about
Toxin-based therapeutic approachesInhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activitiesChannel-forming bacterial toxins in biosensing and macromolecule deliveryReceptors of anthrax toxin and cell entry.Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.Vector-mediated selective expression of lethal factor, a toxic element of Bacillus anthracis, damages A549 cells via inhibition of MAPK and AKT pathways.Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.Cellular and systemic effects of anthrax lethal toxin and edema toxin.Breaking the wall: targeting of the endothelium by pathogenic bacteria.Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cellsMechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions.
P2860
Q27013664-08433737-0AAC-421F-92E3-CD3305E08A57Q33590611-DC856406-FE88-4DA8-8C56-82D4D58D9769Q33927058-EC702265-05AD-4EA2-99AF-7D38F2CB4BDCQ34063766-6D11D609-C5E9-432E-BCD0-C1D82E469EA2Q34101821-15F2758B-5DEB-4B92-AC2E-ABEBDBB722A0Q34659076-644CF7EE-71BE-4D81-A644-6AC74BD4B191Q35155807-D4CC72E4-7A91-41C2-92EB-6A7DE994FB0DQ36545204-F941DFB3-CD91-4CB3-8EEB-09413DDF3E22Q36619196-44F57C7D-8FD8-4621-8CBB-CE976C4F2099Q36829224-4947416C-57E4-4005-8C39-8C2BF0809F04Q37178467-1D1B34FA-D377-4497-BCB3-D6A29703DF0AQ37375271-736F779C-F206-416C-93F7-AE755034B904Q37441837-34ADCE24-22D7-4024-8AD8-85BE606332CCQ37664468-CEB69D18-79D2-4284-B1E8-014C6D531EFCQ40052584-F00B3925-6350-4238-BF2B-29DF0FE9D5EEQ41972670-FC144832-DEA5-469E-9F0D-1C36004DC28FQ50129416-4A9D1002-2A16-4BD2-AF2B-854091D5E6C1
P2860
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@en
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@nl
type
label
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@en
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@nl
prefLabel
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@en
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@nl
P50
P356
P1433
P1476
Potent inhibition of tumor ang ...... for broad anti-tumor efficacy.
@en
P2093
Randall W Alfano
P304
P356
10.4161/CC.7.6.5627
P577
2008-01-18T00:00:00Z